CDKN3, ANLN, SLC2A1 were differentially expressed in tumor tissues and normal tissues of esophageal cancer (ESCA), gastric carcinoma (STAD), clear cell carcinoma of the kidney (KIRC), squamous lung cancer (LUSC), hepatocellular carcinoma (LIHC), adenocarcinoma of the rectum (READ), cholangiocarcinoma (CHOL), and were expressed higher in tumor tissues than in normal tissues. Here, CDKN3 is linked to hepatocellular carcinoma.